Paperpal Prime Logo

Lung Cancer: Targets and Therapy : Impact Factor & More

eISSN: 1179-2728pISSN: 1179-2728
JournalOpen Access

Key Metrics

CiteScore
6.5
SNIP
1.15
Recommended pre-submission checks
Powered by Paperpal by Editage

Lung Cancer: Targets and Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher DOVE MEDICAL PRESS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2390
Publication Time16
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2008
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Lung Cancer: Targets and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Lung Cancer: Targets and Therapy

Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study
  • 13 Oct 2026
  • Lung Cancer: Targets and Therapy
Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung Cancer
  • 2 Sep 2026
  • Lung Cancer: Targets and Therapy
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?
  • 1 Sep 2026
  • Lung Cancer (Auckland, N.Z.)
Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy.
  • 1 Sep 2026
  • Lung Cancer (Auckland, N.Z.)
Unilateral Scleral Icterus as a Rare Presentation of Choroidal Metastasis in Transdifferentiated EGFR-Mutant Lung Cancer: A Case Report and Review of the Literature
  • 28 Aug 2026
  • Lung Cancer: Targets and Therapy
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available \u2013 Practical Dose Selection Considerations and Real-World Access Challenges
  • 28 May 2026
  • Lung Cancer: Targets and Therapy
Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study
  • 13 Oct 2026
  • Lung Cancer: Targets and Therapy
Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung Cancer
  • 2 Sep 2026
  • Lung Cancer: Targets and Therapy
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?
  • 1 Sep 2026
  • Lung Cancer (Auckland, N.Z.)
Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy.
  • 1 Sep 2026
  • Lung Cancer (Auckland, N.Z.)
Unilateral Scleral Icterus as a Rare Presentation of Choroidal Metastasis in Transdifferentiated EGFR-Mutant Lung Cancer: A Case Report and Review of the Literature
  • 28 Aug 2026
  • Lung Cancer: Targets and Therapy
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available \u2013 Practical Dose Selection Considerations and Real-World Access Challenges
  • 28 May 2026
  • Lung Cancer: Targets and Therapy

FAQs on Lung Cancer: Targets and Therapy